Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

AACE sends petition to Congress opposing new Medicare policy

The American Association of Clinical Endocrinologists (AACE) sent a petition to Congress today signed by 1,325 AACE members, non-AACE member physicians, allied health professionals and patients opposing a new Medicare policy which would eliminate consultation codes for specialists.

13 Jan 2010

Growth hormone deficiency can lead to memory deficits later in life

Scientists have shown that early growth hormone supplementation in rats with growth hormone deficiency can prevent defects in memory developing later in adulthood. The study, published in the Journal of Endocrinology is the first to show that memory defects in adults as a result of growth hormone deficiency arising in childhood can be prevented by growth hormone treatment during adolescence.

13 Jan 2010

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

NeuroScience launches NEI Guided Nutrition Program

NeuroScience, Inc. has launched a comprehensive and customizable dietary program based on patients' food sensitivity test results. The NEI Guided Nutrition Program(TM) is the first offering through NeuroScience, Inc.'s new NEI Nutrition(TM) division.

12 Jan 2010

Salt Lake City research center joins international drug trial program for painful menstrual cramps

A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school.

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

A leading clinical research center in Austin has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Exercise may improve cognitive function

Moderate physical activity performed in midlife or later appears to be associated with a reduced risk of mild cognitive impairment, whereas a six-month high-intensity aerobic exercise program may improve cognitive function in individuals who already have the condition, according to two reports in the January issue of Archives of Neurology, one of the JAMA/Archives journals.

11 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

A holistic approach to weight loss

When your New Year's resolution to lose weight crumbles as fast as the cookie touching your lips, it's time to admit that diets don't work. More successful is a holistic approach to losing weight that lets you feel good about feeding your body the nourishment it craves.

8 Jan 2010

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.

8 Jan 2010

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received a $1 million milestone payment from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that expired on December 31, 2009.

8 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

Exercise, nutrition and hormone optimization are key to improve men's health issues

Grant Mansell was 46 and frustrated with his 300 pound physique, ensuing back pain, rising cholesterol, dependency on blood pressure medicine but most of all not enjoying life with his wife and children.

8 Jan 2010

Study suggests pomegranates may prevent growth of breast cancer cells

US scientists have carried out a series of laboratory tests suggesting that natural compounds in pomegranates may prevent the growth of breast cancer cells.

7 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

Hormone News and Research

Further Reading

AACE sends petition to Congress opposing new Medicare policy

Growth hormone deficiency can lead to memory deficits later in life

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

NeuroScience launches NEI Guided Nutrition Program

Salt Lake City research center joins international drug trial program for painful menstrual cramps

Multigene test results impact physicians and patients' decisions on breast cancer therapy

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Exercise may improve cognitive function

Immune cells causes inflammation in thyroid-associated ophthalmopathy

Fibrocytes associated with Graves' disease

A holistic approach to weight loss

Aneeve Nanotechnologies selected to work in the UCLA on-campus Technology Incubator Program

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Exercise, nutrition and hormone optimization are key to improve men's health issues

Study suggests pomegranates may prevent growth of breast cancer cells

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News